Kronos Bio Investor Relations Material
Latest events
Status Update
Kronos Bio
Q1 2025
16 Jul, 2025
Q4 2024
17 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Kronos Bio Inc
Access all reports
Kronos Bio Inc. is a U.S.-based biotechnology company focused on the discovery and development of therapies for cancer and other serious diseases. The company specializes in targeting dysregulated transcription factors and other key regulatory proteins involved in disease progression. Using its proprietary drug discovery platform, Kronos Bio aims to develop small-molecule therapies that address unmet medical needs. Its research spans early discovery through clinical development. The company is headquartered in San Mateo, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
KRON
Country
🇺🇸 United States